Europe — EMA
Ovamex Theramex (Ganirelix)
GNH USA supplies Ovamex Theramex (Ganirelix), a GnRH antagonist for controlled ovarian stimulation and prevention of premature LH surge in IVF cycles.
Request sourcing
What is Ganirelix?
Ganirelix, the active ingredient in Ovamex Theramex, is a GnRH antagonist presented as an injectable solution for subcutaneous use. It is employed in controlled ovarian stimulation protocols within assisted reproductive technology to prevent premature luteinizing hormone surges and to optimise egg retrieval in women undergoing in‑vitro fertilisation.
GNH USA supplies Ovamex Theramex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable products.
What is Ganirelix used for?
Ganirelix is a GnRH antagonist used in assisted reproductive technology to manage ovarian stimulation.
- Controlled ovarian stimulation: Enables precise timing of follicular development and improves oocyte yield during ART cycles. - Prevention of premature LH surge: Suppresses luteinizing hormone release to avoid early ovulation in IVF protocols.
What are the side effects of Ganirelix?
Ganirelix may cause a range of adverse reactions, most of which are mild and transient.
Common Side Effects: - Injection site pain or erythema: mild discomfort at the subcutaneous injection site. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate tension‑type headache. - Hot flashes: transient warmth and sweating. - Abdominal discomfort: mild cramps or bloating. - Mild ovarian cyst formation: small functional cysts that resolve spontaneously.
Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome: severe ovarian enlargement with fluid shifts. - Anaphylactic reaction: rare but potentially life‑threatening allergy. - Severe abdominal pain: may indicate complications such as ovarian torsion. - Thromboembolic events: rare clot formation in veins or arteries.
What precautions apply to Ganirelix?
When using Ganirelix, clinicians should observe several safety measures.
- Assess ovarian response: monitor follicular growth with serial ultrasound. - Avoid in patients with hypersensitivity: do not administer to individuals allergic to ganirelix or formulation excipients. - Use under specialist supervision: restrict to ART programmes managed by qualified reproductive specialists. - Consider renal or hepatic impairment: increase monitoring frequency in patients with organ dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.
What does Ganirelix interact with?
Ganirelix can interact with other agents used in fertility treatment and hormonal regulation.
Major Interactions (Avoid): - Co‑administration with GnRH agonists: may diminish antagonist efficacy. - Concurrent hormonal contraceptives: can interfere with intended LH/FSH suppression.
Moderate Interactions (Monitor Closely): - Use with other fertility drugs (e.g., hCG): monitor for signs of ovarian hyperstimulation. - Concomitant anticoagulants: observe for altered bleeding risk. - Antihistamines: may mask mild injection‑site reactions.



